Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Safety of SARS-CoV-2 mRNA-1273 Vaccine in the US: Active Surveillance, Signal Refinement and Self-Controlled Risk Interval (SCRI) Signal Evaluation in HealthVerity

NCT04958954 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT04958954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04958954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Safety of SARS-CoV-2 mRNA-1273 Vaccine in the US: Active Surveillance, Signal Refinement and Self-Controlled Risk Interval (SCRI) Signal Evaluation in HealthVerity
Lead sponsor
ModernaTX, Inc.
Phase
Observational
Overall status
Completed
Start date
July 7, 2021
Completion date
June 30, 2023
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2